325 results
8-K
INVA
Innoviva Inc
4 Sep 12
Other Events
12:00am
) combination in reducing COPD exacerbations
Exhibit 99.2
Safety of fluticasone furoate (FF), an inhaled corticosteroid in combination with vilanterol (VI … ), a long-acting beta agonist in management of COPD exacerbations
Exhibit 99.3
Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI
8-K
EX-99
INVA
Innoviva Inc
28 Jul 11
Results of Operations and Financial Condition
12:00am
RELOVAIR® 6-month efficacy and safety studies in COPD that support the progression of the program. Theravance also reported that telavancin, a treatment … .
In COPD
The registrational program in COPD consists of five studies, including two 12-month exacerbation studies, two six-month efficacy and safety
8-K
EX-99
INVA
Innoviva Inc
17 Oct 14
Other Events
12:00am
study comparing the efficacy and safety of Anoro® Ellipta® (umeclidinium /vilanterol, 'UMEC/VI'), the combination long-acting muscarinic antagonist … , multicenter study to assess the efficacy and safety of UMEC/VI 62.5/25mcg inhalation powder administered once-daily in the dry powder inhaler, Ellipta®
8-K
EX-99.2
INVA
Innoviva Inc
26 Sep 11
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation in COPD
12:00am
of COPD.
OBJECTIVES
· To assess the safety/tolerability (primary) and pharmacokinetics (secondary) of repeat once-daily doses of inhaled GSK573719 … criteria included: past or present disease likely to affect the safety of the patient or influence study outcomes; positive pre-study drug/alcohol
8-K
EX-99
INVA
Innoviva Inc
22 Sep 10
Other Events
12:00am
a Phase II safety and efficacy study for developmental combination treatment Relovair in chronic obstructive pulmonary disorder (COPD).(1) Relovair … and asthma.
Study Results
The Relovair (FFVI 400/25mcg) COPD Phase II study showed that the effect of FFVI on heart function and safety (as measured
8-K
EX-99.16
eu5p1hy
4 Sep 12
Other Events
12:00am
8-K
EX-99.5
yu26rf1h
20 Sep 10
Fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), demonstrates once-daily efficacy in asthma when dosed in the evening
12:00am
8-K
EX-99.4
834j4amcznceypkp
20 Sep 10
Fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), demonstrates once-daily efficacy in asthma when dosed in the evening
12:00am
8-K
EX-99.9
bk1wka8 yn
4 Sep 12
Other Events
12:00am
8-K
EX-99.4
tzu9u7q4c1e6mpq
22 May 12
Other Events
12:00am
8-K
EX-99.1
i0glew
18 May 10
Other Events
12:00am
8-K
EX-99
3n3v6
21 Apr 10
Results of Operations and Financial Condition
12:00am
8-K
EX-99.2
0crgu9 b6z
8 Sep 14
Other Events
12:00am
8-K
EX-99
aw5b2wrjlc
27 Oct 11
Results of Operations and Financial Condition
12:00am
8-K
EX-99
58p9sb3usfor6r9
6 Feb 14
Results of Operations and Financial Condition
12:00am
8-K
s8wtjh 6zn
22 May 12
Other Events
12:00am
8-K
EX-99.1
fydsixj
2 Jul 12
Other Events
12:00am
8-K
EX-99.4
sl0 cnkykbc
26 Sep 11
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation in COPD
12:00am
8-K
EX-99.3
7qikg3g
20 Sep 10
Fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), demonstrates once-daily efficacy in asthma when dosed in the evening
12:00am
8-K
EX-99
9axmwba1bgxc6ww
10 Oct 06
Theravance Announces Additional Results From Successful Phase 3 Telavancin Complicated Skin and Skin Structure Program
12:00am